COH-SR4 - CAS:73439-19-7

您当前的位置：

COH-SR4

目录号 : KM5576 CAS No. : 73439-19-7 纯度 : 98%

Data Sheet 产品使用指南

COH-SR4 是一种 AMPK 活化剂。COH-SR4 对白血病、黑色素瘤、乳腺癌和肺癌显示出强大的抗增殖活性。COH-SR4 通过激活 AMPK 来抑制脂肪细胞分化，有望用于肥胖及代谢紊乱相关的研究。

规格	价格	是否有货
25mg		In-stock
50mg		In-stock
100mg		In-stock
200mg	询价	In-stock
500mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide B In-stock
Isoginkgetin In-stock
Ginkgolic acid C17:1 In-stock
Ginkgolic Acid In-stock
Propargyl-PEG4-amine In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.

体外研究

COH-SR4 (1-5 μM; 24 hours) results in a dose-dependent increase in the phosphorylation of AMPK and its substrate ACC in 3T3-L1 preadipocytes, as well as in cancer cells such as HL-60, HeLa, MCF-7.
COH-SR4 (3-5 µM; 7 days) significantly inhibits 3T3-L1 adipocyte differentiation in a dose-dependent manner.
COH-SR4 (1-5 μM; 24 hours) promotes cell G1 cycle arrest.
COH-SR4 significantly reduces intracellular lipid accumulation and downregulates the expression of key adipogenesis-related transcription factors and lipogenic proteins.

Western Blot Analysis

Cell Line:	3T3-L1 preadipocytes, HL-60 cells, HeLa cells, MCF-7 cells
Concentration:	1 μM, 3 μM, 5 μM
Incubation Time:	24 hours
Result:	Indirectly activated AMPK.

Cell Cycle Analysis

Cell Line:	3T3-L1 cells
Concentration:	1 μM, 3 μM, 5 μM
Incubation Time:	24 hours
Result:	Modulated the level of proteins active during S and G2 phases of the cell cycle.

体内研究

COH-SR4 (5 mg/kg; i.g.; 3x/week; for 6 weeks) reduces body weight and fat mass in high fat diet (HFD) obese mice without affecting food intake.
COH-SR4 improves glycemic control and dyslipidemia in HFD obese mice.
COH-SR4 decreases adipose tissue hypertrophy and affects circulating adipokine levels in HFD obese mice.
COH-SR4 prevents hepatic lipid accumulation and fatty liver in HFD obese mice.

Animal Model:	Nine-week old male C57BL/6J mice
Dosage:	5 mg/kg
Administration:	Oral gavage, three times a week, for 6 weeks
Result:	Decreased body weight and fat mass in HFD obese mice.

分子式

C₁₃H₈N₂OCl₄

分子量

350.03

CAS号

73439-19-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (357.11 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8569 mL	14.2845 mL	28.5690 mL
5 mM	0.5714 mL	2.8569 mL	5.7138 mL
10 mM	0.2857 mL	1.4284 mL	2.8569 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.08 mg/mL (5.94 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (5.94 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.94 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.94 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。